EP4213831A1 - Supplément pour le traitement d'une infection à coronavirus - Google Patents
Supplément pour le traitement d'une infection à coronavirusInfo
- Publication number
- EP4213831A1 EP4213831A1 EP20780975.7A EP20780975A EP4213831A1 EP 4213831 A1 EP4213831 A1 EP 4213831A1 EP 20780975 A EP20780975 A EP 20780975A EP 4213831 A1 EP4213831 A1 EP 4213831A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- day
- mmol
- use according
- dose
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000011282 treatment Methods 0.000 title claims abstract description 39
- 239000013589 supplement Substances 0.000 title description 14
- 208000001528 Coronaviridae Infections Diseases 0.000 title description 5
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims abstract description 89
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims abstract description 81
- 229960004308 acetylcysteine Drugs 0.000 claims abstract description 81
- 235000020956 nicotinamide riboside Nutrition 0.000 claims abstract description 61
- 239000011618 nicotinamide riboside Substances 0.000 claims abstract description 61
- 239000000203 mixture Substances 0.000 claims abstract description 59
- JLEBZPBDRKPWTD-TURQNECASA-O N-ribosylnicotinamide Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](CO)O2)O)=C1 JLEBZPBDRKPWTD-TURQNECASA-O 0.000 claims abstract description 58
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims abstract description 47
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims abstract description 36
- 229960004203 carnitine Drugs 0.000 claims abstract description 33
- 238000002560 therapeutic procedure Methods 0.000 claims abstract description 32
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims abstract description 30
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims abstract description 27
- JHPNVNIEXXLNTR-UHFFFAOYSA-N 4-(trimethylammonio)butanoate Chemical compound C[N+](C)(C)CCCC([O-])=O JHPNVNIEXXLNTR-UHFFFAOYSA-N 0.000 claims abstract description 26
- OKJIRPAQVSHGFK-UHFFFAOYSA-N N-acetylglycine Chemical compound CC(=O)NCC(O)=O OKJIRPAQVSHGFK-UHFFFAOYSA-N 0.000 claims abstract description 26
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 claims abstract description 26
- 235000001968 nicotinic acid Nutrition 0.000 claims abstract description 24
- 239000011664 nicotinic acid Substances 0.000 claims abstract description 24
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 claims abstract description 19
- 239000004471 Glycine Substances 0.000 claims abstract description 18
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims abstract description 18
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims abstract description 16
- 235000018417 cysteine Nutrition 0.000 claims abstract description 16
- 241000711573 Coronaviridae Species 0.000 claims abstract description 15
- 235000005152 nicotinamide Nutrition 0.000 claims abstract description 15
- 239000011570 nicotinamide Substances 0.000 claims abstract description 15
- 229960003966 nicotinamide Drugs 0.000 claims abstract description 15
- OITBLCDWXSXNCN-UHFFFAOYSA-N 4-trimethylammoniobutanal Chemical compound C[N+](C)(C)CCCC=O OITBLCDWXSXNCN-UHFFFAOYSA-N 0.000 claims abstract description 13
- PUEDDPCUCPRQNY-ZYUZMQFOSA-O D-ribosylnicotinic acid Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1[N+]1=CC=CC(C(O)=O)=C1 PUEDDPCUCPRQNY-ZYUZMQFOSA-O 0.000 claims abstract description 13
- 239000004472 Lysine Substances 0.000 claims abstract description 13
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims abstract description 13
- MXNRLFUSFKVQSK-QMMMGPOBSA-O N(6),N(6),N(6)-trimethyl-L-lysine Chemical compound C[N+](C)(C)CCCC[C@H]([NH3+])C([O-])=O MXNRLFUSFKVQSK-QMMMGPOBSA-O 0.000 claims abstract description 13
- FFDGPVCHZBVARC-UHFFFAOYSA-N N,N-dimethylglycine Chemical compound CN(C)CC(O)=O FFDGPVCHZBVARC-UHFFFAOYSA-N 0.000 claims abstract description 13
- JJIHLJJYMXLCOY-BYPYZUCNSA-N N-acetyl-L-serine Chemical compound CC(=O)N[C@@H](CO)C(O)=O JJIHLJJYMXLCOY-BYPYZUCNSA-N 0.000 claims abstract description 13
- DAYLJWODMCOQEW-TURQNECASA-N NMN zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)([O-])=O)O2)O)=C1 DAYLJWODMCOQEW-TURQNECASA-N 0.000 claims abstract description 13
- BZQFBWGGLXLEPQ-UHFFFAOYSA-N O-phosphoryl-L-serine Natural products OC(=O)C(N)COP(O)(O)=O BZQFBWGGLXLEPQ-UHFFFAOYSA-N 0.000 claims abstract description 13
- 108010077895 Sarcosine Proteins 0.000 claims abstract description 13
- 229960003237 betaine Drugs 0.000 claims abstract description 13
- 229960003067 cystine Drugs 0.000 claims abstract description 13
- SENPVEZBRZQVST-HISDBWNOSA-O deamido-NAD(+) Chemical compound [N+]1([C@@H]2O[C@@H]([C@H]([C@H]2O)O)COP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@@H]([C@@H]2O)O)N2C=3N=CN=C(C=3N=C2)N)=CC=CC(C(O)=O)=C1 SENPVEZBRZQVST-HISDBWNOSA-O 0.000 claims abstract description 13
- 229950006137 dexfosfoserine Drugs 0.000 claims abstract description 13
- 108700003601 dimethylglycine Proteins 0.000 claims abstract description 13
- JOUIQRNQJGXQDC-ZYUZMQFOSA-L nicotinate D-ribonucleotide(2-) Chemical compound O1[C@H](COP([O-])([O-])=O)[C@@H](O)[C@@H](O)[C@@H]1[N+]1=CC=CC(C([O-])=O)=C1 JOUIQRNQJGXQDC-ZYUZMQFOSA-L 0.000 claims abstract description 13
- BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 claims abstract description 13
- GJAWHXHKYYXBSV-UHFFFAOYSA-N quinolinic acid Chemical compound OC(=O)C1=CC=CN=C1C(O)=O GJAWHXHKYYXBSV-UHFFFAOYSA-N 0.000 claims abstract description 13
- 229940043230 sarcosine Drugs 0.000 claims abstract description 13
- PHIQHXFUZVPYII-ZCFIWIBFSA-O (R)-carnitinium Chemical compound C[N+](C)(C)C[C@H](O)CC(O)=O PHIQHXFUZVPYII-ZCFIWIBFSA-O 0.000 claims abstract 11
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 claims abstract 7
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 claims abstract 7
- 229960001153 serine Drugs 0.000 claims description 66
- 239000000126 substance Substances 0.000 claims description 54
- 238000000034 method Methods 0.000 claims description 36
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 claims description 24
- 241001678559 COVID-19 virus Species 0.000 claims description 18
- 208000025721 COVID-19 Diseases 0.000 claims description 13
- 229960002449 glycine Drugs 0.000 claims description 11
- XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 claims description 11
- 229960004171 hydroxychloroquine Drugs 0.000 claims description 11
- 241000008910 Severe acute respiratory syndrome-related coronavirus Species 0.000 claims description 9
- 239000003443 antiviral agent Substances 0.000 claims description 6
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 claims description 5
- 229960003677 chloroquine Drugs 0.000 claims description 5
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 claims description 5
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 63
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 37
- 230000009469 supplementation Effects 0.000 description 28
- 230000000694 effects Effects 0.000 description 27
- 229960003180 glutathione Drugs 0.000 description 18
- BAWFJGJZGIEFAR-NNYOXOHSSA-O NAD(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-O 0.000 description 16
- 239000000902 placebo Substances 0.000 description 16
- 229940068196 placebo Drugs 0.000 description 16
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 14
- 210000004185 liver Anatomy 0.000 description 13
- 229950006238 nadide Drugs 0.000 description 13
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 13
- 229960003512 nicotinic acid Drugs 0.000 description 12
- 230000003247 decreasing effect Effects 0.000 description 11
- 239000000843 powder Substances 0.000 description 11
- 229960001518 levocarnitine Drugs 0.000 description 10
- 230000036470 plasma concentration Effects 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 230000001965 increasing effect Effects 0.000 description 9
- 206010019708 Hepatic steatosis Diseases 0.000 description 8
- 241000282412 Homo Species 0.000 description 8
- 108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 description 8
- 102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 230000007774 longterm Effects 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 7
- 108010024636 Glutathione Proteins 0.000 description 7
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 7
- 230000007423 decrease Effects 0.000 description 7
- 230000002503 metabolic effect Effects 0.000 description 7
- 230000004060 metabolic process Effects 0.000 description 7
- 239000002207 metabolite Substances 0.000 description 7
- 239000002243 precursor Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- 231100000419 toxicity Toxicity 0.000 description 7
- 230000001988 toxicity Effects 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 6
- 206010047700 Vomiting Diseases 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 230000037361 pathway Effects 0.000 description 6
- 230000035935 pregnancy Effects 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- RZALONVQKUWRRY-FYZOBXCZSA-N 2,3-dihydroxybutanedioic acid;(3r)-3-hydroxy-4-(trimethylazaniumyl)butanoate Chemical compound OC(=O)C(O)C(O)C(O)=O.C[N+](C)(C)C[C@H](O)CC([O-])=O RZALONVQKUWRRY-FYZOBXCZSA-N 0.000 description 5
- 230000002411 adverse Effects 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 208000037584 hereditary sensory and autonomic neuropathy Diseases 0.000 description 5
- 201000000965 hereditary sensory and autonomic neuropathy type 1 Diseases 0.000 description 5
- 235000015263 low fat diet Nutrition 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- 230000036542 oxidative stress Effects 0.000 description 5
- 230000003612 virological effect Effects 0.000 description 5
- 208000035473 Communicable disease Diseases 0.000 description 4
- 206010012735 Diarrhoea Diseases 0.000 description 4
- 208000004852 Lung Injury Diseases 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 206010035664 Pneumonia Diseases 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 229940024606 amino acid Drugs 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 230000008753 endothelial function Effects 0.000 description 4
- 230000037406 food intake Effects 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 230000028709 inflammatory response Effects 0.000 description 4
- 231100000515 lung injury Toxicity 0.000 description 4
- 238000010197 meta-analysis Methods 0.000 description 4
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 208000023504 respiratory system disease Diseases 0.000 description 4
- 238000003757 reverse transcription PCR Methods 0.000 description 4
- 238000012552 review Methods 0.000 description 4
- 208000016505 systemic primary carnitine deficiency disease Diseases 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 150000003626 triacylglycerols Chemical class 0.000 description 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 4
- QTJKCQPXTOYYHJ-BYPYZUCNSA-N (2r)-2-acetamido-3-nitrososulfanylpropanoic acid Chemical compound CC(=O)N[C@H](C(O)=O)CSN=O QTJKCQPXTOYYHJ-BYPYZUCNSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 206010058892 Carnitine deficiency Diseases 0.000 description 3
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 208000010201 Exanthema Diseases 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 108010053070 Glutathione Disulfide Proteins 0.000 description 3
- 206010019280 Heart failures Diseases 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 206010022489 Insulin Resistance Diseases 0.000 description 3
- 241000711466 Murine hepatitis virus Species 0.000 description 3
- 206010028372 Muscular weakness Diseases 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 102000015785 Serine C-Palmitoyltransferase Human genes 0.000 description 3
- 108010024814 Serine C-palmitoyltransferase Proteins 0.000 description 3
- 206010069363 Traumatic lung injury Diseases 0.000 description 3
- 208000003455 anaphylaxis Diseases 0.000 description 3
- 230000000840 anti-viral effect Effects 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 235000015872 dietary supplement Nutrition 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 238000009511 drug repositioning Methods 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 201000005884 exanthem Diseases 0.000 description 3
- 206010016256 fatigue Diseases 0.000 description 3
- YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 description 3
- 229960002297 fenofibrate Drugs 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 235000021472 generally recognized as safe Nutrition 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- YPZRWBKMTBYPTK-BJDJZHNGSA-N glutathione disulfide Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(O)=O)CSSC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O YPZRWBKMTBYPTK-BJDJZHNGSA-N 0.000 description 3
- 238000001631 haemodialysis Methods 0.000 description 3
- 235000009200 high fat diet Nutrition 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 208000019423 liver disease Diseases 0.000 description 3
- 238000011068 loading method Methods 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 238000002705 metabolomic analysis Methods 0.000 description 3
- 230000001431 metabolomic effect Effects 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 231100000062 no-observed-adverse-effect level Toxicity 0.000 description 3
- 229960005489 paracetamol Drugs 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 206010037844 rash Diseases 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 230000029058 respiratory gaseous exchange Effects 0.000 description 3
- 230000009897 systematic effect Effects 0.000 description 3
- 230000008673 vomiting Effects 0.000 description 3
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 102100035765 Angiotensin-converting enzyme 2 Human genes 0.000 description 2
- 108090000975 Angiotensin-converting enzyme 2 Proteins 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 102000004506 Blood Proteins Human genes 0.000 description 2
- 108010017384 Blood Proteins Proteins 0.000 description 2
- 208000035985 Body Odor Diseases 0.000 description 2
- 208000031229 Cardiomyopathies Diseases 0.000 description 2
- 102000003952 Caspase 3 Human genes 0.000 description 2
- 108090000397 Caspase 3 Proteins 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 208000002881 Colic Diseases 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 201000003883 Cystic fibrosis Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 206010013710 Drug interaction Diseases 0.000 description 2
- 208000032928 Dyslipidaemia Diseases 0.000 description 2
- 208000004930 Fatty Liver Diseases 0.000 description 2
- 101000613614 Homo sapiens Protein mono-ADP-ribosyltransferase PARP10 Proteins 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 208000017170 Lipid metabolism disease Diseases 0.000 description 2
- 241000127282 Middle East respiratory syndrome-related coronavirus Species 0.000 description 2
- 208000010428 Muscle Weakness Diseases 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 241000283966 Pholidota <mammal> Species 0.000 description 2
- 102100040847 Protein mono-ADP-ribosyltransferase PARP10 Human genes 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 241000315672 SARS coronavirus Species 0.000 description 2
- 206010040047 Sepsis Diseases 0.000 description 2
- 206010040904 Skin odour abnormal Diseases 0.000 description 2
- 208000024780 Urticaria Diseases 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 238000011225 antiretroviral therapy Methods 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 231100000676 disease causative agent Toxicity 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 230000037149 energy metabolism Effects 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 238000013265 extended release Methods 0.000 description 2
- 208000010706 fatty liver disease Diseases 0.000 description 2
- 238000011010 flushing procedure Methods 0.000 description 2
- 230000004907 flux Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 229920001903 high density polyethylene Polymers 0.000 description 2
- 239000004700 high-density polyethylene Substances 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 230000037353 metabolic pathway Effects 0.000 description 2
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 2
- 210000003470 mitochondria Anatomy 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 230000002028 premature Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 150000003839 salts Chemical group 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- UYPYRKYUKCHHIB-UHFFFAOYSA-N trimethylamine N-oxide Chemical compound C[N+](C)(C)[O-] UYPYRKYUKCHHIB-UHFFFAOYSA-N 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- GADIJPCDIWZEMB-BTNVMJJCSA-N (2r,3r)-2,3-dihydroxybutanedioate;hydron;(3r)-3-hydroxy-4-(trimethylazaniumyl)butanoate Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.C[N+](C)(C)C[C@H](O)CC([O-])=O.C[N+](C)(C)C[C@H](O)CC([O-])=O GADIJPCDIWZEMB-BTNVMJJCSA-N 0.000 description 1
- PHIQHXFUZVPYII-LURJTMIESA-N (S)-carnitine Chemical compound C[N+](C)(C)C[C@@H](O)CC([O-])=O PHIQHXFUZVPYII-LURJTMIESA-N 0.000 description 1
- YABIFCKURFRPPO-IVOJBTPCSA-N 1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyridin-1-ium-3-carboxamide;chloride Chemical compound [Cl-].NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](CO)O2)O)=C1 YABIFCKURFRPPO-IVOJBTPCSA-N 0.000 description 1
- OSJPPGNTCRNQQC-UWTATZPHSA-N 3-phospho-D-glyceric acid Chemical compound OC(=O)[C@H](O)COP(O)(O)=O OSJPPGNTCRNQQC-UWTATZPHSA-N 0.000 description 1
- 208000018828 3-phosphoglycerate dehydrogenase deficiency Diseases 0.000 description 1
- 208000007788 Acute Liver Failure Diseases 0.000 description 1
- 206010000804 Acute hepatic failure Diseases 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 208000007082 Alcoholic Fatty Liver Diseases 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 206010002216 Anaphylactoid reaction Diseases 0.000 description 1
- 206010002388 Angina unstable Diseases 0.000 description 1
- 208000028185 Angioedema Diseases 0.000 description 1
- 208000031504 Asymptomatic Infections Diseases 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000112286 Bat SARS-like coronavirus Species 0.000 description 1
- 241000112287 Bat coronavirus Species 0.000 description 1
- 241000008904 Betacoronavirus Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 208000009079 Bronchial Spasm Diseases 0.000 description 1
- 208000014181 Bronchial disease Diseases 0.000 description 1
- 206010006482 Bronchospasm Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 101710147349 Carnitine transporter Proteins 0.000 description 1
- 241000288673 Chiroptera Species 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 1
- 208000006154 Chronic hepatitis C Diseases 0.000 description 1
- 208000002330 Congenital Heart Defects Diseases 0.000 description 1
- 241000314928 Cordyline virus 1 Species 0.000 description 1
- 206010011703 Cyanosis Diseases 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 208000032274 Encephalopathy Diseases 0.000 description 1
- 208000037487 Endotoxemia Diseases 0.000 description 1
- 206010016262 Fatty liver alcoholic Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010016825 Flushing Diseases 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 235000016623 Fragaria vesca Nutrition 0.000 description 1
- 240000009088 Fragaria x ananassa Species 0.000 description 1
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 1
- 229940123457 Free radical scavenger Drugs 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 1
- 102000018899 Glutamate Receptors Human genes 0.000 description 1
- 108010027915 Glutamate Receptors Proteins 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 108700009884 Hypoadiponectinemia Proteins 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 241000712431 Influenza A virus Species 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 239000004201 L-cysteine Substances 0.000 description 1
- 235000013878 L-cysteine Nutrition 0.000 description 1
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 235000019687 Lamb Nutrition 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 208000007466 Male Infertility Diseases 0.000 description 1
- 208000025370 Middle East respiratory syndrome Diseases 0.000 description 1
- 208000007379 Muscle Hypotonia Diseases 0.000 description 1
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 1
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 1
- 125000003047 N-acetyl group Chemical group 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 238000011887 Necropsy Methods 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- RDHQFKQIGNGIED-MRVPVSSYSA-N O-acetyl-L-carnitine Chemical compound CC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C RDHQFKQIGNGIED-MRVPVSSYSA-N 0.000 description 1
- 206010030209 Oesophageal varices Diseases 0.000 description 1
- 206010034107 Pasteurella infections Diseases 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 208000005764 Peripheral Arterial Disease Diseases 0.000 description 1
- 201000011252 Phenylketonuria Diseases 0.000 description 1
- 206010035039 Piloerection Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 206010062237 Renal impairment Diseases 0.000 description 1
- 108091006736 SLC22A5 Proteins 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- 102000010821 Solute Carrier Family 22 Member 5 Human genes 0.000 description 1
- 239000004376 Sucralose Substances 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical class IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 1
- 208000030886 Traumatic Brain injury Diseases 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 208000007814 Unstable Angina Diseases 0.000 description 1
- 206010046274 Upper gastrointestinal haemorrhage Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 208000037919 acquired disease Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 208000024716 acute asthma Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 206010069351 acute lung injury Diseases 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 208000026594 alcoholic fatty liver disease Diseases 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 210000002821 alveolar epithelial cell Anatomy 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000010425 asbestos Substances 0.000 description 1
- 230000000923 atherogenic effect Effects 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 206010064097 avian influenza Diseases 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000002715 bioenergetic effect Effects 0.000 description 1
- 238000003766 bioinformatics method Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000002302 brachial artery Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000010001 cellular homeostasis Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000002886 cheminformatics method Methods 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- 235000015111 chews Nutrition 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 150000001840 cholesterol esters Chemical class 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000011443 conventional therapy Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 239000007938 effervescent tablet Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 206010016165 failure to thrive Diseases 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 238000012252 genetic analysis Methods 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 231100000024 genotoxic Toxicity 0.000 description 1
- 230000001738 genotoxic effect Effects 0.000 description 1
- 230000024924 glomerular filtration Effects 0.000 description 1
- 229940045883 glutathione disulfide Drugs 0.000 description 1
- 108010087860 glutathione receptor Proteins 0.000 description 1
- 229960003711 glyceryl trinitrate Drugs 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 230000010224 hepatic metabolism Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 208000010710 hepatitis C virus infection Diseases 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 208000006575 hypertriglyceridemia Diseases 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 201000004332 intermediate coronary syndrome Diseases 0.000 description 1
- 230000035987 intoxication Effects 0.000 description 1
- 231100000566 intoxication Toxicity 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000001057 ionotropic effect Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 150000004668 long chain fatty acids Chemical class 0.000 description 1
- 231100000298 lowest-observed-adverse-effect level Toxicity 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000004065 mitochondrial dysfunction Effects 0.000 description 1
- 230000004898 mitochondrial function Effects 0.000 description 1
- 210000001700 mitochondrial membrane Anatomy 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 230000037023 motor activity Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 238000000491 multivariate analysis Methods 0.000 description 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 1
- 230000036473 myasthenia Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 230000004719 natural immunity Effects 0.000 description 1
- 230000004112 neuroprotection Effects 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 229940101270 nicotinamide adenine dinucleotide (nad) Drugs 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 229940100688 oral solution Drugs 0.000 description 1
- 230000001956 orexigenic effect Effects 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000010627 oxidative phosphorylation Effects 0.000 description 1
- YPZRWBKMTBYPTK-UHFFFAOYSA-N oxidized gamma-L-glutamyl-L-cysteinylglycine Natural products OC(=O)C(N)CCC(=O)NC(C(=O)NCC(O)=O)CSSCC(C(=O)NCC(O)=O)NC(=O)CCC(N)C(O)=O YPZRWBKMTBYPTK-UHFFFAOYSA-N 0.000 description 1
- 208000012237 paracetamol poisoning Diseases 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 230000009038 pharmacological inhibition Effects 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 238000013081 phylogenetic analysis Methods 0.000 description 1
- 230000005371 pilomotor reflex Effects 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 238000009597 pregnancy test Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 210000001147 pulmonary artery Anatomy 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 238000006479 redox reaction Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000012959 renal replacement therapy Methods 0.000 description 1
- 230000008672 reprogramming Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229910052895 riebeckite Inorganic materials 0.000 description 1
- 210000005241 right ventricle Anatomy 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 235000014102 seafood Nutrition 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 229940124547 specific antidotes Drugs 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 238000011301 standard therapy Methods 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 238000010972 statistical evaluation Methods 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 1
- 235000019408 sucralose Nutrition 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- -1 thiol compound Chemical class 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 239000005495 thyroid hormone Substances 0.000 description 1
- 229940036555 thyroid hormone Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- 231100000440 toxicity profile Toxicity 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000009529 traumatic brain injury Effects 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 230000036325 urinary excretion Effects 0.000 description 1
- MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 description 1
- 229960000604 valproic acid Drugs 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 244000052613 viral pathogen Species 0.000 description 1
- 230000007485 viral shedding Effects 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 1
- 229960005080 warfarin Drugs 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 238000012070 whole genome sequencing analysis Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
Definitions
- the present disclosure relates to the treatment of a subject that is or has been infected with a coronavirus.
- Coronaviruses are a large family of ribonucleic acid viruses that typically cause mild to moderate upper respiratory diseases in humans. Members of this family are known to infect animals, including dogs, chickens, cattle, pigs, cats, pangolins, and bats. As far as we know, seven members of this family can infect humans and cause illness. Of these, HC0V-229E, -OC43, -NL63 and -HKUi species cause mild respiratory diseases in humans. However, severe acute respiratory syndrome (SARS) that occurred in late 2002; Middle East Respiratory Syndrome (MERS-CoV) that emerged in 2012; and SARS-C0V-2, which appeared in China in December 2019, are the species that may cause serious respiratory diseases in humans. The epidemic of COVID-19 spread globally in a short time that classified as a pandemic by the World Health Organization (WHO). Since the beginning of the outbreak, infections have expanded rapidly into multiple simultaneous epidemics worldwide.
- WHO World Health Organization
- SARS-C0V-2 has 79.5% homology to SARS-C0V-1, the causative agent of SARS in south China; 85% to 96% identity with bat-SL-CoVZC45, a bat SARS-like coronavirus, and 91.02% similarity with SARS- CoV-2-like coronavirus in pangolin named Pangolin-CoV.
- a population genetic analysis of 103 SARS-C0V-2 genomes from China revealed that causative agent of COVID-19 consists of two evolution types.
- Type L (70% prevalence in Wuhan), which is derived from the ancestral type S (30% prevalence in Wuhan), is more aggressive and contagious.
- Zhou et al. investigated the COVID-19 agent through full genome sequencing and phylogenetic analysis, classifying it as a betacoronavirus (a positivesense, single-stranded RNA virus), the same subgenus as SARS-CoV as well as several bat coronaviruses.
- SARS-C0V-2 uses the same receptor binding (angiotensin-converting enzyme 2 (ACE2)) and cell entry pathway as SARS- CoV-1.
- ACE2 angiotensin-converting enzyme 2
- MERS-CoV is less closely related to SARS- C0V-2.
- SARS-C0V-2 has been found in stool and blood samples, but the rate of transmission, period of infectivity, and duration of viral shedding are uncertain and show great variation.
- drug repurposing provides an alternative source of data for a novel understanding of metabolic reprogramming in viral infections, as well as the organic compounds with previously unrecognized antiviral behaviours that are possible to expand in unveiling properties of virus biology.
- drug repurposing identifies formerly undiscovered biomolecular networks, transforming them into novel pharmaceutical targets, even though the determined molecules may not be implemented into clinical trials.
- Glycine can be synthesized via the interconversion of serine. It has been shown that the serine synthesis is downregulated in patients with NAFLD and supplementation of serine has attenuated alcoholic fatty liver by enhancing homocysteine metabolism in mice and rats. Depleted liver GSH is also restored by the administration of N- acetylcysteine as in acetaminophen poising. L-carnitine and nicotinamide riboside that both stimulate the transfer of fatty acids from cytosol to mitochondria have been identified as two additional cofactors that are depleted in patients.
- N-acetyl cysteine also known as acetylcysteine
- NAC N-acetyl cysteine
- acetylcysteine is the N-acetyl derivative of the amino acid L-cysteine and a precursor in the formation of the antioxidant glutathione in the body.
- administration of acetylcysteine replenishes glutathione stores.
- Glutathione may act as endogenous neuromodulator, may also modulate the redox state of the NMDA receptor complex, activate ionotropic receptors that are different from any other excitatory amino acid receptor, and which may constitute glutathione receptors, potentially making it a neurotransmitter.
- N- acetylcysteine is a prodrug of glutathione, it may modulate all of the aforementioned receptors as well. It confers antioxidant effects and is able to reduce free radicals.
- Acetylcysteine also possesses some anti-inflammatory effects possibly via inhibiting NF-KB and modulating cytokine synthesis.
- NAC has two approved indications: (1) treatment of paracetamol (acetaminophen) overdose associated liver damage, and (2) to loosen thick mucus in individuals with cystic fibrosis or chronic obstructive pulmonary disease.
- NAC has also been tested for contrast induced nephropathy, infertility, cystic fibrosis, ischemic heart diseases, HIV, hypercholesterolemia and schizophrenia. It is probably beneficial in any kind of acute hepatic failure. NAC usage in liver disease is discussed below.
- NAC is a thiol compound that acts directly as a free radical scavenger and as a precursor to reduced glutathione (GSH). This molecule has been shown to reduce the number and effect of COPD exacerbations and also the inflammatory response in epithelial cells exposed to the H5N1 influenza A virus.
- NAC improves inflammatory response and oxidative stress in patients with community-acquired pneumonia compared to conventional therapy.
- HDX aspartic acid-P-hydroxamate, an inhibitor of endogenous SO2 generating enzyme
- HDX failed to promote alveolar epithelial cell radical generation, PARP upregulation, caspase-3 activation or apoptosis, suggesting that the downregulated SO2 pathway markedly facilitated the oxidative stress and thus likely induced apoptosis.
- NAC is soluble in water and alcohol, and practically insoluble in chloroform and ether. It is a white to white with light yellow cast powder and has a pKa of 9.5 at 30 °C. NAC is stable in gastric and intestinal fluids and rapidly absorbed after oral administration. It is not affected by food intake. It reaches peak plasma concentration in 30-60 minutes after application. The distribution volume (Vd) is between 0.33 and 0.47 L/kg, which is evident in extracellular fluids and passes primarily to the lung, kidney, and liver. After oral administration, 48% of the amount passed to the blood is determined in the lungs. The rate of binding to plasma proteins is about 50%. NAC is extensively liver metabolized, and 22-30% is excreted in urine in the form of sulfate and taurine. NAC has a half-life of 5.6-6 hours in adults.
- NAC is available as intravenous and oral formulations.
- the IV injection and inhalation preparations are, in general, prescription only, whereas the oral solution and the effervescent tablets are available over the counter in many countries including the United States.
- Daily dose of NAC is 200 mg capsules taken 3 times a day (morning, lunch, evening) or a single dose of 600 mg (3 capsules) in the evening.
- the loading dose is -140 mg/kg
- the maintenance dose is 70 mg/kg every 4 hours (17 doses).
- NAC has been tested in various doses.
- NAC supplementation has been given at a dose of 2700 mg/day for 6 months in a double-blind randomized controlled trial.
- NAC supplementation is used to enhance performance in elite sport.
- a recent review of the literature evaluated the effect of NAC supplementation.
- the typical daily dose of NAC reported was 5.8 g/day; with a range between 1.2 and 20.0 g/day.
- effect of NAC supplementation on oxidative stress status and alveolar inflammation was analyzed in a double-blind, randomized clinical trial using a dose of 1800 mg/day for 4 months.
- NAC was administered in oral doses of 6,000- 8,000 mg daily for several months. It had a good safety profile, adverse effects were minimal and not significantly associated with NAC ingestion.
- NAC is contraindicated in patients with previous allergic/anaphylactoid reaction to acetylcysteine. Patients with acute asthma attacks can also not use NAC. Pregnancy risk category of NAC is B. There is insufficient data on the usage in pregnancy and lactation. Therefore, it should only be used if it is very necessary. Drug interaction with acetylcysteine is very rare. Minor interactions have been reported with parenteral nitro-glycerine and oral forms of nitrates. NAC has no effect on the use of vehicles and machinery.
- L-carnitine is a naturally occurring substance required in mammalian energy metabolism. It is a carrier molecule that facilitates the transport of long-chain fatty acids across the inner mitochondrial membrane, thereby delivers substrate for oxidation and subsequent energy production.
- Carnitine deficiency is characterized with very low L-carnitine levels in plasma and tissues and may be either primary or secondary.
- Primary carnitine deficiency is an autosomal recessive disorder caused by a deficiency in the plasma membrane carnitine transporter and leads to urinary carnitine wasting.
- SLC22A5 mutations can also affect carnitine transport and decrease carnitine levels.
- Secondary carnitine deficiency is associated with various causes like inadequate intake, decreased synthesis due to liver disorders, loss of carnitine during diarrhoea, diuresis or haemodialysis.
- the clinical presentation consists of recurrent episodes of Reye-like encephalopathy, hypoketotic hypoglycaemia, and/or cardiomyopathy.
- Associated symptoms include hypotonia, muscle weakness and failure to thrive.
- carnitine supplementation may rapidly alleviate signs and symptoms.
- L-carnitine is indicated in the treatment of primary and secondary L-carnitine deficiency. It may also be used in patients taking certain drugs (such as valproic acid for seizures or antibiotics for tuberculosis), or during medical procedures (haemodialysis for kidney disease) that deplete the body's L-carnitine. (27)
- L-carnitine has also been tested in heart failure, ischemic heart diseases, peripheral arterial diseases, HIV, male infertility, anorexia, chronic fatigue syndrome and fatigue associated with chronic diseases and chronic obstructive pulmonary disease. It is also used as a replacement supplement in strict vegetarians, dieters, and low-weight or premature infants. In athletes, carnitine has been used to improve performance, but beneficial effects in athletes is not consisted in all studies.
- Levocarnitine is a white crystalline, hygroscopic powder. It is readily soluble in water, hot alcohol, and insoluble in acetone.
- the absolute bioavailability of levocarnitine is ⁇ 15-16%.
- the mean distribution half-life is ⁇ 0.6 hours and the mean apparent terminal elimination halflife is 17.4 hours.
- Total body clearance of levocarnitine (Dose/AUC including endogenous baseline concentrations) is a mean of 4.00 L/h.
- Levocarnitine is not bound to plasma protein or albumin when tested at any concentration.
- Major metabolites are trimethylamine N-oxide, primarily in urine (8% to 49% of the administered dose) and [3H]-y-butyrobetaine, primarily in faeces (0.44% to 45% of the administered dose).
- Urinary excretion of levocarnitine is about 4 to 8% of the dose.
- Faecal excretion of total carnitine is less than 1% of the administered dose.
- a levocarnitine dosage of 1 to 3 g/day has been recommended for a 50 kg subject.
- L-carnitine supplementation has been given at a dose of 6 g/ day for 2 weeks.
- Several studies have tested if L-carnitine supplementation promotes weight loss in obese subjects (4 g/L, 8 weeks).
- Efficacy and effectiveness of carnitine supplementation for cancer-related fatigue has recently been tested in a systematic literature review and meta-analysis (nine studies used a dose between 2 to 6 g per day).
- Impact of L-carnitine supplementation on plasma lipoprotein(a) concentrations have been analysed in a recent systematic review and meta-analysis of randomized controlled trials (studies used 2-4 g/day).
- L-carnitine is usually well tolerated.
- Various mild gastrointestinal complaints have been reported during the long-term administration of oral L- or D-carnitine; these include transient nausea and vomiting, abdominal cramps, and diarrhoea.
- carnitine supplements can cause nausea, vomiting, abdominal cramps, diarrhoea, and a “fishy” body odor.
- Rarer side effects include muscle weakness/mild myasthenia in uremic patients and seizures in those with seizure disorders.
- Gastrointestinal adverse reactions with levocarnitine may be avoided by a slow consumption of the solution or by a greater dilution. Decreasing the dosage often diminishes or eliminates drug-related patient body odor or gastrointestinal symptoms when present. Tolerance should be monitored very closely during the first week of administration, and after any dosage increases.
- NAD consuming activities and cell division necessitate ongoing NAD synthesis, either through a de novo pathway that originates with tryptophan or via salvage pathways from three NAD+ precursor vitamins, nicotinamide riboside, nicotinamide, and nicotinic acid.
- NAD generation is vital since it is linked to several redox reactions in the body. NAD plays a central role in energy metabolism and oxidative phosphorylation and is a key component of many metabolic pathways for carbohydrates, lipids, and amino acids.
- NR has been used as an NAD+ precursor vitamin.
- NR is considered a form of vitamin B3 (niacin) and it is available as an over-the-counter dietary supplement, and approved as food ingredient in enhanced water products, protein shakes, nutrition bars, gum and chews at no more than 0.027% by weight.
- Human blood NAD+ can rise as much as 2.7-fold with a single oral dose of NR in a pilot study, and single doses of 100, 300 and 1,000 mg of NR produce dose-dependent increases in the blood NAD+ metabolome in the first clinical trial of NR pharmacokinetics in humans.
- Niacin has been reported to alleviate LPS-induced acute lung injury, possibly by preventing the depletion of NAD.
- a randomized controlled study determined the short-term effects of extended-release niacin (ERN) on endothelial function, measured by flow-mediated vasodilation (FMD) of the brachial artery, in HIV-infected adults with low HDL-c.
- FMD flow-mediated vasodilation
- PARP enzymes are enzymes that induce natural immunity against mouse hepatitis virus (MHV), which is used as a coronavirus infection model. MHV infection has been shown to increase NAD and NADP in natural immune cells. Study data show that overexpression of virally induced PARP and PARP10 depress host cell NAD metabolism and NAD + enhancement strategies differ in restoring PARP10. These data showed that, not nuclear NAD +, but the cytoplasmic NAD+ increase can regulate antiviral PARP functions that support the natural immune response to other viruses and coronaviruses susceptible to PARP-mediated antiviral activity.
- a typical dose maybe 100-250 mg taken before the first meal of the day.
- a 90-day study was performed comparing NR at 300, 1000, and 3000 mg/kg/day to an equimolar dose of nicotinamide at 1260 mg/kg/day as a positive control. Results from the study show that NR had a similar toxicity profile to nicotinamide at the highest dose tested.
- the lowest observed adverse effect level for NR was 1000 mg/kg/day, and the no observed adverse effect level was 300 mg/kg/day.
- Flushing is the most sensitive end point of nicotinic acid effects, but after ingestion of supplemental nicotinamide, no cases of flushing or glucose intolerance have been reported and only one case of hepatitis was reported following the ingestion of greater than 3 g/ day for several days. Such side-effects have not been reported for NR.
- NR was not defined as genotoxic but data on the use of NAD during pregnancy and breast-feeding is inadequate.
- European Food Safety Authority (EFSA) EFSA has issued a positive opinion of nicotinamide riboside chloride as a novel food on August 07, 2019. And a dose of 230 mg/ day in pregnant and lactating women is permissible (EFSA Opinion: https://www.efsa. europa.eu/en/efsajournal/pub/5775).
- L-serine is generally classified as a non-essential amino acid, however under certain circumstances, vertebrates cannot synthesize it in sufficient quantities to meet necessary cellular demands. L-serine is biosynthesized in the mammalian central nervous system from 3-phosphoglycerate and serves as a precursor for the synthesis of the amino acids glycine and cysteine.
- HSAN1 Hereditary sensory and autonomic neuropathy type 1
- SPT serine palmitoyl transferase
- L-serine has been shown to decrease the macrophage- and neutrophil-mediated inflammatory responses in mice during Pasteurella multocida infection.
- L-serine administration has been reported to reduce body weight by decreasing orexigenic peptide expression and reduces oxidative stress and inflammation during aging in mice, possibly by modulating the Sirti/NFicB pathway.
- IL-6 and the number of GFAP- and Iba-i-positive cells) by L-serine treatment has been shown to lead to neuroprotection in mice after traumatic brain injury.
- the study subjects were randomized to L-serine (400 mg/kg/day) or placebo for one year. All participants received L-serine during the second year. Analysis of vital signs, physical examination findings, and clinical laboratory examinations, did not reveal adverse effects of L-serine. Thus, long-term L-serine supplementation did not reveal adverse effects of L-serine.
- Serine supplementation (three daily doses of 5 g of L-serine [i.e., 190 mg/kg]) has also been shown to be safe even in pregnancy, as shown by in pre- and postnatal treatment of 3-phosphoglycerate-dehydrogenase deficiency.
- the present inventors have recently integrated kinetic data from human turn-over studies using stable-isotope technique with experimentally derived flux data to simulate the dynamics of liver metabolism of subjects with varying degree of hepatic steatosis using personalized liver genome-scale metabolic models (GEMs).
- GEMs liver genome-scale metabolic models
- the correlations between the predicted intracellular fluxes of the liver and hepatic steatosis were assessed to identify underlying molecular mechanisms that are disturbed in subjects with NAFLD.
- the systems level analysis indicated that altered NAD+ and GSH metabolism (with increased demand for NAD+ and GSH in NAFLD) was a prevailing feature in NAFLD.
- the present inventors modelled and validated if it would be possible to reverse hepatic steatosis by boosting the NAD+ and GSH metabolism (as described above). Advanced modelling was performed to clarify the molar relationship of the co-factors needed for optimal efficiency. It was found that the metabolites serine, L- carnitine, NAC and NR in a molar ratio of 30:4:4:1 may effectively promote NAD+ and GSH metabolism and decrease the amount of hepatic steatosis.
- suitable daily supplementation doses are 24.7 g serine (0.0078 x 30 moles), 5.1 g of L- carnitine (given in the stable salt form of 7.46 g L-carnitine tartrate) (0.0078 x 4 moles), 5.1 g of NAC (0.0078 x 4 moles) and 2 g of NR (0.0078 moles). This is further discussed below.
- ODE differential equation
- Model fit to the mean plasma serine level predicted that a twice-daily dose of 12.4 g serine might produce a desired long-term increase in mean plasma serine concentration of 100%. Doses up to 400 mg/kg/day (around 25-30 g/day) have been studied in humans and shown to be safe.
- L-carnitine deoxycarnitine gamma-butyrobetaine, 4- trimethylammoniobutanal, 3-hydroxy-N 6,N6,N6- trimethyl-L-lysine, N6,N6,N6-trimethyl-L-lysine and/or lysine
- composition for use in a therapeutic method, said composition comprising:
- nicotinamide riboside quinolinate, deamino-NAD+, nicotinate D-ribonucleotide, nicotinamide D-ribonucleotide, nicotinate D-ribonucleoside, nicotinamide and/ or nicotinate.
- the therapeutic method is a method of treatment of a subject that is or has been infected with a coronavirus or a method of treatment of a subject suffering from a SARS.
- Figure 1 shows a Kaplan-Meier graph of the proportion of patients in the treated group and the placebo group that had symptoms on each day.
- a composition for use in a therapeutic method is: a method of treatment of a subject that is or has been infected with a coronavirus, typically a severe acute respiratory syndrome-related coronavirus; or a method of treatment of a subject suffering from a severe acute respiratory syndrome (SARS).
- a coronavirus typically a severe acute respiratory syndrome-related coronavirus
- SARS severe acute respiratory syndrome
- SARS is a viral respiratory disease of zoonotic origin caused by a severe acute respiratory syndrome coronavirus.
- the SARS is COVID-19.
- the severe acute respiratory syndrome-related coronavirus is severe acute respiratory syndrome coronavirus 2 (SARS-C0V-2).
- composition of the first aspect comprises:
- nicotinamide riboside quinolinate, deamino-NAD+, nicotinate D-ribonucleotide, nicotinamide D-ribonucleotide, nicotinate D-ribonucleoside, nicotinamide and/or nicotinate.
- the composition comprises A), B), C) and optionally D).
- group A serine and glycine are preferred.
- the most preferred substance in group A) is serine, which is typically provided as L-serine.
- N-acetyl cysteine (NAC) and cysteine are preferred.
- the most preferred substance in group B) is NAC.
- the substance of group C) is preferably carnitine, optionally in the form of a carnitine salt, such as carnitine tartrate.
- the substance of group C) is L-carnitine, optionally in the form of a L-carnitine salt, such as L-carnitine tartrate.
- the substance of group D) is preferably nicotinamide riboside (NR).
- the substance(s) of group A) is preferably included in a higher molar amount than the substance(s) of group D).
- the molar ratio of A) to D) is normally between 250:1 and 1.5:1 and typically between 150:1 and 3:1.
- the molar ration is between 90:1 and 10:1, more preferably between 50:1 and 20:1.
- the molar ratio of A) to B), considering efficacy and toxicity, is typically between 20:1 and 1:4, such as between 16:1 and 1:4, preferably between 12:1 and 1.5:1 and more preferably between 10:1 and 3:1.
- A) to C), considering efficacy and toxicity, is normally between 150:1 and 1:1, typically between 100:1 and 2:1, preferably between 30:1 and 3:1, more preferably between 15:1 and 4:1.
- the composition of the first aspect is a solid, such as a solid powder. Such a powder can be mixed with water, e.g. by the patient/consumer, a nurse or a physician.
- the composition of the first aspect is an aqueous solution or suspension (“cocktail”), which facilitates convenient oral administration. Such an aqueous solution or suspension is preferably ready to drink.
- the composition is a powder comprising:
- D) nicotinamide riboside wherein the molar ratio of A) to B) is between 16:1 and 1.5:1, preferably between 10:1 and 3:1, the molar ratio of A) to C) is between 100:1 and 2:1, preferably between 30:1 and 3:1, more preferably between 15:1 and 4:1; and the molar ratio of A) to D) is between 150:1 and 3:1, preferably between 90:1 and 10:1, more preferably between 50:1 and 20:1.
- the composition is a powder comprising: A) serine;
- D) nicotinamide riboside wherein the molar ratio of A) to D) is between 90:1 and 10:1, preferably between 50:1 and 20:1, more preferably between 40:1 and 20:1.
- the concentration of A) is typically 0.20-2.4 mmol/ml, preferably 0.40-2.4 mmol/ml and more preferably 0.60-2.4 mmol/ml;
- the concentration of B) is normally 0.09-0.90 mmol/ml, typically 0.09-0.54 mmol/ml, preferably 0.11-0.40 mmol/ml and more preferably 0.013-0.30 mmol/ml; and/or
- the concentration of D) is typically 0.006-0.12 mmol/ml, preferably 0.012-0.08 mmol/ml and more preferably 0.018-0.07 mmol/ml.
- the concentration of C) is normally 0.009-0.38 mmol/ml, typically 0.009-0.19 mmol/ml, preferably 0.016-0.16 mmol/ml and more preferably 0.028-0.12 mmol/ml.
- the solution or suspension of the first aspect may be provided in a package for convenient handling and distribution. Further, the volume of such a package may be such that drinking the whole contents of the package at once or during a single day results in oral administration of appropriate doses of the substances in the solution or suspension.
- the volume of the package is 25-1000 ml. The volume is preferably 50-500 ml. When it is intended that the consumer/ patient shall drink more than one package per day, the volume is typically relatively low, such as 25-500 ml, preferably 25-400 ml.
- the packaged solution or suspension comprises 48- 478 mmol of A).
- the dose of A) is effective, but not toxic.
- A) is serine in an amount of 5-50 g, more preferably 10-50 g.
- the packaged solution or suspension comprises 2.0-39.2 mmol of D) when D) is NR and 2.0-196 mmol of D) when D) is not NR.
- the dose of D) is effective, but not toxic.
- D) is NR in an amount of 0.5-10 g, more preferably 1.5-6 g.
- the composition of the first aspect is a powder, it may also be packaged.
- the powder maybe provided in unit dose packs. It follows from the discussion above that such a unit dose may comprise 48-478 mmol of A) and/ or 2.0-39.2 mmol of D) when D) is NR and 2.0-196 mmol of D) when D) is not NR.
- such as packed powder preferably comprises serine in an amount of 5- 50 g and/or NR in an amount of 0.5-10 g. More preferably, such a packed powder comprises serine in an amount of 10-50 g and/or NR in an amount of 1.5-6. o g.
- the substances of the present disclosure are preferably a significant part of the composition of the first aspect.
- the substances included in groups A)-D) may amount to at least 10 %, such as at least 25 %, such as at least 50 % of the dry weight of the composition of the first aspect.
- the weight of serine is at least 10 %, such as at least 25 %, such as at least 40 % of the dry weight of the composition of the first aspect.
- composition of the first aspect may comprise one or more tasting agent(s), such as one or more sweetener(s) (e.g. sucralose) and/or one or more flavor agent(s). It may also comprise a lubricant, such as a polyethylene glycol lubricant (e.g. Polyglykol 8000 PF (Clariant)).
- a lubricant such as a polyethylene glycol lubricant (e.g. Polyglykol 8000 PF (Clariant)).
- the therapeutic method comprises oral administration of the composition.
- the therapeutic method of the first aspect may further comprise administration of an anti-viral drug.
- the therapeutic method of the first aspect further comprises administration of chloroquine or hydroxychloroquine.
- the daily dose maybe in the range of 100-1200 mg, such as 200- 1000 mg.
- hydroxychloroquine maybe given for a period of 2-8 days, such as 3-7 days.
- the therapeutic method may for example comprise administration, such as oral administration, of:
- the method of treatment may for example comprise administration, such as oral administration, of:
- C) may be administrated in a dose of 12-100 mmol/ day, such as 16-75 mmol/day, such as 20-50 mmol/day
- the daily dose may be reached by administrating one or more doses per day to the patient.
- the number of daily doses is one, two or three.
- the patient may consume a drink formed from the composition in powderous form one, two or three times per day.
- Each dose or drink preferably comprises no more than 4.78 mmol/kg of A).
- the method of treatment may for example be carried out for a period of at least one week.
- the first administration of the composition of the first aspect is carried out within 48 hours, such as within 24 hours, of the diagnosis of a coronavirus infection, such as a SARS-C0V-2 infection.
- a coronavirus infection such as a SARS-C0V-2 infection.
- Such a diagnosis may be RT-PCR-based.
- substances comprising
- the therapeutic method is: a method of treatment of a subject suffering from a severe acute respiratory syndrome (SARS); or a method of treatment of a subject that is or has been infected with a coronavirus, typically a severe acute respiratory syndrome-related coronavirus.
- SARS severe acute respiratory syndrome
- a method of treating a subject comprising administration to the subject of:
- nicotinamide riboside quinolinate, deamino-NAD+, nicotinate D-ribonucleotide, nicotinamide D-ribonucleotide, nicotinate D-ribonucleoside, nicotinamide and/or nicotinate.
- the subject of the method is a subject suffering from a SARS or a subject that is or has been infected with a coronavirus.
- the embodiments and examples of the first and second aspect apply to the third aspect mutatis mutandis.
- the subject of the first, second and third aspect is preferably a human subject.
- a mixture of the four substances was produced in Turkey according to GMP regulations by Pharmactive Company, Istanbul (www.pharmactive.com.tr/en/anasayfa.html) according to EU standards and packed according to GMP rules with the appropriate dosage.
- the mixture was produced as a soluble powder packed in 60 mL HDPE plastic bottles with screw caps.
- the mixture contained strawberry aroma.
- Placebo products were produced at Pharmactive company using identical HDPE plastic bottles. Placebo products contained to be dissolved in 200 mL water.
- the scope of the trial is 400 volunteering patients (men and women) aged 18 years or older, who have been diagnosed with COVID-19, meet all the inclusion criteria and do not meet any of the exclusion criteria.
- 100 patients were randomized and recruited. Provided that the statistical evaluation of the data obtained from the 100 patients are found to be satisfactory, a second stage of the study including an additional 300 patients will be carried out.
- - Severe liver disease e.g. Child Pugh score > C, AST>5 times upper limit
- the study subjects were randomized on a 3:1 basis.
- the study was open- labeled.
- a web-based randomization system was used to assign a randomization code for each patient.
- the investigator or another responsible person at the investigational site entered the web-based randomization system specific to the study through assigned username and password. After entering patient-related information (patient number, date of birth, patient initials), the system provided a randomization code for the future use.
- the first treatment (initial loading dose) was administrated by the responsible investigator based on the randomisation assignment. The remaining treatments were administered by the patient at home. Hydroxychloroquine treatment was administered at an initial dose of 2x400 mg (oral) followed by 400 mg/day (2x200 mg oral) for a total of 5 days.
- the present disclosure can present results from the first stage of the clinical trial. On average, the patients of the treated group were asymptomatic after 6.6 days. In contrast, the patients of the placebo group were on average asymptomatic after 9.3 days.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La présente divulgation porte sur une composition destinée à être utilisée dans une méthode thérapeutique de traitement d'un sujet qui est ou qui a été infecté par un coronavirus, ladite composition comprenant : A) de la sérine, de la glycine, de la bétaïne, de la N-acétylglycine, de la N-acétylsérine, de la diméthylglycine, de la sarcosine et/ou de la phosphosérine ; B) de la N-acétylcystéine, de la cystéine et/ou de la cystine ; C) facultativement de la carnitine, de la désoxycarnitine, de la gamma-butyrobétaïne, du 4-triméthylammoniobutanal, de la 3-hydroxy-N6,N6,N6-triméthyl-L-lysine, de la N6,N6,N6-triméthyl-L-lysine et/ou de la lysine ; et D) du nicotinamide riboside, du quinolinate, du désamino-NAD+, du nicotinate D-ribonucléotide, du nicotinamide D-ribonucléotide, du nicotinate D-ribonucléoside, du nicotinamide et/ou du nicotinate.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/EP2020/076194 WO2022058026A1 (fr) | 2020-09-18 | 2020-09-18 | Supplément pour le traitement d'une infection à coronavirus |
Publications (1)
Publication Number | Publication Date |
---|---|
EP4213831A1 true EP4213831A1 (fr) | 2023-07-26 |
Family
ID=72659793
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP20780975.7A Pending EP4213831A1 (fr) | 2020-09-18 | 2020-09-18 | Supplément pour le traitement d'une infection à coronavirus |
Country Status (2)
Country | Link |
---|---|
EP (1) | EP4213831A1 (fr) |
WO (1) | WO2022058026A1 (fr) |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112190696A (zh) * | 2020-02-21 | 2021-01-08 | 浙江三誉生物科技有限公司 | 一种预防或治疗新型冠状病毒的药物组合物及其用途 |
-
2020
- 2020-09-18 EP EP20780975.7A patent/EP4213831A1/fr active Pending
- 2020-09-18 WO PCT/EP2020/076194 patent/WO2022058026A1/fr unknown
Also Published As
Publication number | Publication date |
---|---|
WO2022058026A1 (fr) | 2022-03-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Gould et al. | Impact of supplementary amino acids, micronutrients, and overall diet on glutathione homeostasis | |
Alves et al. | Glycine metabolism and its alterations in obesity and metabolic diseases | |
Summar et al. | Inborn errors of metabolism with hyperammonemia: urea cycle defects and related disorders | |
Bockbrader et al. | A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin | |
Veeneman et al. | Protein intake during hemodialysis maintains a positive whole body protein balance in chronic hemodialysis patients | |
Wan et al. | Pellagra: a review with emphasis on photosensitivity | |
Ianiro et al. | Levothyroxine absorption in health and disease, and new therapeutic perspectives. | |
Widmer et al. | Oseltamivir in seasonal, avian H5N1 and pandemic 2009 A/H1N1 influenza: pharmacokinetic and pharmacodynamic characteristics | |
CN109310653A (zh) | 用于控制释放半胱胺和***治疗半胱胺敏感性病症的组合物 | |
US20050070607A1 (en) | N-acetylcysteine compositions and methods for the treatment and prevention of cysteine/glutathione deficiency in diseases and conditions | |
CN1329030C (zh) | 肝癌发生·发展抑制剂 | |
US9572848B1 (en) | Composition of matter for sexual dysfunction | |
Rahimi et al. | Hepatic encephalopathy: pharmacological therapies targeting ammonia | |
TW202025997A (zh) | 正常化胺基酸代謝的方法 | |
BR112020011055A2 (pt) | tetratiomolibdato de bis-colina para tratar doença de wilson | |
MX2011004678A (es) | Formulaciones complementarias antivirales. | |
WO2004019928A1 (fr) | Agent pour le traitement des maladies hepatiques | |
Teplan et al. | Enhanced metabolic effect of erythropoietin and keto acids in CRF patients on low-protein diet: Czech multicenter study | |
Manitpisitkul et al. | Pharmacokinetics of topiramate in patients with renal impairment, end-stage renal disease undergoing hemodialysis, or hepatic impairment | |
RU2372900C2 (ru) | Ингибитор возникновения и развития рака печени для применения у пациентов-людей с циррозом печени, положительных по вирусу гепатита с | |
Bottiglieri et al. | S-adenosylmethionine | |
Hardy et al. | Nutraceuticals: a pharmaceutical viewpoint: I | |
Shetty et al. | Mechanisms and therapeutics of n-acetylcysteine: a recent update | |
US20220088044A1 (en) | Substances for treatment of coronavirus infection | |
Rahimi et al. | Novel ammonia-lowering agents for hepatic encephalopathy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20230418 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) |